27 September 2020
Veterinary Chemistry Analyzer Market Forecast 2020-2030: Forecasts and Analysis By Type, By Product, By Application and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Veterinary Chemistry Analyzer sector analysis.
According to the report published by Visiongain, the Veterinary Chemistry Analyzer market was valued at approximately USD xx million in 2019 and is expected to grow at a CAGR of around xx% between 2020 and 2030. As clinic blood samples are used, health and safety rules require universal precautions to be observed during the treatment of the samples at all times. The handling of reagent disk used and the parts of a sample-contacting analyzer shall be treated according to the applicable local regulations or standard procedures of the affiliated units.
Clinical Veterinary Chemistry Analyzer provides compact, portable and rapidly reporting results in clinical testing laboratories for medical facilities and veterinary clinics. A photometric measuring technology of precision, in combination with the utilization of specific reagent disks, is used for the portable design of the clinical analyzer. The disco includes a collection of dry reagents used in standardized blood sample analyses for specific biomarkers.
Dry Chemistry Analyzers Are Considered More Economical to Low-Throughput Applications Than Wet-Chemistry Analyzers
Continuous advances in diagnostic technology have both increased the reliability of the instrument and the frequency of its internal use in clinical veterinary practice. The most frequently used hematological and biochemical analyzers in first opinion practices have the advantages of being quick and largely cost-effective. In general, dry chemistry analyzers are considered more economical to low-throughput applications than wet-chemistry analyzers. Large wet chemical analyzers offer significant savings at low reagent cost in reference laboratories with large numbers of samples. The relatively rapid expiration of these reagents when opened does not however prevent its application in low-performance laboratories, as considerable waste would compensate any savings. For veterinary in-house usage, a smaller wet-reagent analysis is available, although independent performance assessment studies have not yet been published in our knowledge. The Catalyst One is a clinical chemistry analyst that uses dry slide technology. It is an in-clinical chemistry analyzer. The dry-chemical techniques require less maintenance compared to wet chemistry analyzers and therefore are ideally suited for doctoral testing in veterinary practice in general. An internal centrifugal system that allows the loading of full blood into the analyzer, thus further reducing sample time is also included in this dry-chemistry in-clinic analyzer.
Point analyzers in veterinary medicine are heavily used.
Though there are numerous potential benefits, including fast turnaround times, small sample volumes requirements and unlimited availability, some are inconsistent studies of comparison methods and poor quality assurance measures. Such tools should be used to detect inconsistencies in outcomes that can affect medical interpretation and decision-making, in contrast to the methods developed. This can usually be achieved by method comparison studies using the Deming regression and bland-altman statistics and plots 5. QC validation should be performed on the basis of the analysis and quality requirements of the instrument by point of care analyzers. Analytic performance studies quantify the error in the laboratory methods: precision measures the closeness between repeat results on the same sample; prejudices are the quantification of the difference between the results measured and the' true' result derived from a known standard or reference technique. To determine acceptability of results for commonly measured veterinary analytes, TEobs is then compared to a predefined Total Admissible Error (TEa) limit published in 2013. TEobs must be calculated for each analysis, is unique to every instrument and may be variable by analysis level.
Hospitals have the largest market share and its dominance over the forecast period
Hospitals have the largest market share and its dominance over the forecast period is likely to continue, due to increased demand for domestic analyzers of veterinary chemistry. The demand is raised by an increased awareness of the advantages of in-house analyzers like lower turnaround times and increased safety with pre-anesthetic testing. The increased incidence of diseases such as obesity, renal disease, cancer and animal drug anomalies are some of the main factors that are expected to lead to segment development. According to mypet.com, diabetes is expected from 1 in 100 dogs aged 12, with diabetes from 1 in 50 to 1 in 500 cat. In 2012-2014, diabetes diagnosis in pets has increased by 16% in cats and 32.0% for dogs, according to the survey by the Zoetis Inc. (2012-2014).
North America dominated the industry by adding more than 41.0% of total sales
In 2019, North America dominated the industry by adding more than 39.0% of total sales. A rises in animal health expenditure and increasing demand for animal-based food are some of the key factors responsible for dominating the region. Asia Pacific, due to the increasing animal population, increased animal health awareness and increasing adoption of animals, is planned to be the fastest growing segment of the CAGR with 9.4 percent over the forecast period. The population of pet food in India, for example, was 17 million by 2019, according to India International Pet Trade Affair. In India, 800,000 livestock were taken each year on average.
Competition in the market
The key players focus on new product development and conclude distribution and supply agreements with other players to increase their share of the market. For example, the new lactate test for solo point-of-care instruments was introduced in July 2017 at Eurolyser Diagnostic. Veterinarians working with ill animals regularly, especially dogs and racehorses, are likely to be interested in this test.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.
15 September 2022
The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.